Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

767.76 +10.22 (+1.35%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,942,517
Open 811.35
Bid (Size) 778.76 (1)
Ask (Size) 785.00 (5)
Prev. Close 757.54
Today's Range 766.61 - 811.35
52wk Range 567.42 - 972.53
Shares Outstanding N/A
Dividend Yield 0.68%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans. 
Via Benzinga
Exposures Product Safety
2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves
Via The Motley Fool

Performance

YTD
+29.65%
+29.65%
1 Month
+2.38%
+2.38%
3 Month
-16.41%
-16.41%
6 Month
-13.75%
-13.75%
1 Year
+34.60%
+34.60%

More News

Read More
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Via The Motley Fool
Why Viking Therapeutics Tumbled by More Than 10% This Week
Via The Motley Fool
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?
Via Investor's Business Daily
Exposures Product Safety
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up
Via The Motley Fool
Peering Into Eli Lilly's Recent Short Interest
Via Benzinga
Behind the Scenes of Eli Lilly's Latest Options Trends
Via Benzinga
Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
Via Benzinga
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Via Investor's Business Daily
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
Via Benzinga
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Via Benzinga
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List
Via Investor's Business Daily
Exposures Product Safety
These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?
Via The Motley Fool
This Is Huge News for Eli Lilly Investors
Via The Motley Fool
Who's Next To Join Tesla, Broadcom In $1 Trillion Club? Over 50% Say The World's Biggest Retailer
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Via MarketBeat
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Via Investor's Business Daily
Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug
Via The Motley Fool
Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
Via The Motley Fool
15 Billion Reasons to Love Eli Lilly Stock Right Now
Via The Motley Fool
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
Via Investor's Business Daily
2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.